David Charles Lubner Insider Trading Transactions

FREE EMAIL WATCHDOG

Get free email notifications about insider trading for David Charles Lubner.

Your email is safe with us.
The service is free and you can unsubscribe at any time.

General | Insider Transactions | Monthly Overview

Get the latest insider transactions of David Charles Lubner. David Charles Lubner is SVP and CFO in TETRAPHASE PHARMACEUTICALS INC ($TTPH) and EVP & CFO in Ra Pharmaceuticals, Inc. ($RARX) and Executive V.P. & CFO in Ra Pharmaceuticals, Inc. ($RARX) and Executive VP and CFO in Ra Pharmaceuticals, Inc. ($RARX) and Director in Nightstar Therapeutics plc ($NITE) and Director in Vor Biopharma Inc. ($VOR) and Director in Gemini Therapeutics, Inc. /DE ($FSDC) and Director in Dyne Therapeutics, Inc. ($DYN).

Latest Insider Trading Transactions of David Charles Lubner

	1 Week	2 Weeks	1 Month	3 Months	6 Months	1 Year	2 Years
No. of Purchases	0	0	0	0	0	0	0
Value of Purchases ($)	0	0	0	0	0	0	0
No. of Sales	0	0	0	0	0	0	0
Value of Sales ($)	0	0	0	0	0	0	0

Sentiment: All, DYN, FSDC, NITE, RARX, TTPH, VOR

Page: 1

Date	Ticker	Company	Owner	Relationship	Transaction	Code	Cost ($)	Shares	Transaction Value ($)	Total Shares	% Holdings
May 27 2021	DYN	Dyne Therapeutics, ...	Lubner David Charles	Director	Option Exercise	A	19.56	19,596	383,298	19,596
Apr 07 2021	FSDC	Gemini Therapeutic ...	Lubner David Charles	Director	Option Exercise	A	12.66	58,855	745,104	58,855
Mar 15 2021	FSDC	Gemini Therapeutic ...	Lubner David Charles	Director	Option Exercise	A	17.00	25,000	425,000	25,000
Feb 09 2021	VOR	Vor Biopharma Inc.	Lubner David Charles	Director	Option Exercise	A	18.00	16,900	304,200	16,900
Sep 23 2020	DYN	Dyne Therapeutics, ...	Lubner David Charles	Director	Option Exercise	C	0.00	177,872	0	0
Sep 23 2020	DYN	Dyne Therapeutics, ...	Lubner David Charles	Director	Option Exercise	P	0.00	177,872	0	177,872
Sep 23 2020	DYN	Dyne Therapeutics, ...	Lubner David Charles	Director	Option Exercise	A	5.54	14,444	80,020	14,444
Sep 23 2020	DYN	Dyne Therapeutics, ...	Lubner David Charles	Director	Option Exercise	A	5.54	11,156	61,804	11,156
Sep 23 2020	DYN	Dyne Therapeutics, ...	Lubner David Charles	Director	Buy	C	0.00	53,625	0	53,625	0 to 53.6 K
Apr 03 2020	RARX	Ra Pharmaceuticals ...	Lubner David Charles	Executive VP and CF ...	Option Exercise	D	0.00	10,416	0	0
Apr 03 2020	RARX	Ra Pharmaceuticals ...	Lubner David Charles	Executive VP and CF ...	Option Exercise	D	21.00	133,000	2,793,000	0
Apr 03 2020	RARX	Ra Pharmaceuticals ...	Lubner David Charles	Executive VP and CF ...	Option Exercise	D	7.33	62,500	458,125	0
Apr 03 2020	RARX	Ra Pharmaceuticals ...	Lubner David Charles	Executive VP and CF ...	Option Exercise	D	16.64	112,500	1,872,000	0
Apr 03 2020	RARX	Ra Pharmaceuticals ...	Lubner David Charles	Executive VP and CF ...	Option Exercise	D	5.60	28,571	159,998	0
Apr 03 2020	RARX	Ra Pharmaceuticals ...	Lubner David Charles	Executive VP and CF ...	Option Exercise	D	2.87	92,283	264,852	0
Apr 03 2020	RARX	Ra Pharmaceuticals ...	Lubner David Charles	Executive VP and CF ...	Option Exercise	D	2.87	115,572	331,692	0
Apr 03 2020	RARX	Ra Pharmaceuticals ...	Lubner David Charles	Executive VP and CF ...	Sell	D	48.00	15,622	749,856	0	15.6 K to 0 (-100.00 %)
Jun 07 2019	NITE	Nightstar Therapeu ...	Lubner David Charles	Director	Option Exercise	D	13.57	21,000	284,970	0
Jun 07 2019	NITE	Nightstar Therapeu ...	Lubner David Charles	Director	Option Exercise	D	12.27	18,200	223,314	0
Jun 07 2019	NITE	Nightstar Therapeu ...	Lubner David Charles	Director	Sell	D	25.50	29,124	742,662	0	29.1 K to 0 (-100.00 %)
Feb 05 2019	RARX	Ra Pharmaceuticals ...	Lubner David Charles	Executive V.P. & CF ...	Option Exercise	M	0.00	10,417	0	20,833
Feb 05 2019	RARX	Ra Pharmaceuticals ...	Lubner David Charles	Executive V.P. & CF ...	Option Exercise	A	21.00	133,000	2,793,000	133,000
Feb 05 2019	RARX	Ra Pharmaceuticals ...	Lubner David Charles	Executive V.P. & CF ...	Payment of Exercise	F	21.00	3,291	69,111	7,126	10.4 K to 7.1 K (-31.59 %)
Feb 05 2019	RARX	Ra Pharmaceuticals ...	Lubner David Charles	Executive V.P. & CF ...	Buy	M	0.00	10,417	0	10,417	0 to 10.4 K
Jan 29 2019	NITE	Nightstar Therapeu ...	Lubner David Charles	Director	Option Exercise	A	13.57	21,000	284,970	21,000
Jan 29 2019	NITE	Nightstar Therapeu ...	Lubner David Charles	Director	Option Exercise	A	13.57	21,000	284,970	21,000
Feb 05 2018	RARX	Ra Pharmaceuticals ...	Lubner David Charles	Executive V.P. & CF ...	Option Exercise	A	0.00	31,250	0	31,250
Feb 05 2018	RARX	Ra Pharmaceuticals ...	Lubner David Charles	Executive V.P. & CF ...	Option Exercise	A	7.33	62,500	458,125	62,500
Feb 03 2017	RARX	Ra Pharmaceuticals ...	Lubner David Charles	Executive V.P. & CF ...	Option Exercise	A	16.64	112,500	1,872,000	112,500
Oct 31 2016	RARX	Ra Pharmaceuticals ...	Lubner David Charles	EVP & CFO	Option Exercise	A	2.87	29,285	84,048	29,285
Aug 17 2015	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Option Exercise	M	7.94	9,500	75,430	123,799
Aug 17 2015	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Sell	S	42.92	9,500	407,740	69,270	78.8 K to 69.3 K (-12.06 %)
Aug 17 2015	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Buy	M	7.94	9,500	75,430	78,770	69.3 K to 78.8 K (+13.71 %)
Jul 15 2015	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Option Exercise	M	7.94	1,701	13,506	133,299
Jul 15 2015	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Option Exercise	M	2.03	5,799	11,772	13,744
Jul 15 2015	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Sell	S	48.92	7,500	366,900	69,270	76.8 K to 69.3 K (-9.77 %)
Jul 15 2015	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Buy	M	7.94	1,701	13,506	76,770	75.1 K to 76.8 K (+2.27 %)
Jul 15 2015	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Buy	M	2.03	5,799	11,772	75,069	69.3 K to 75.1 K (+8.37 %)
Jun 16 2015	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Option Exercise	M	2.03	7,500	15,225	19,543
Jun 16 2015	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Sell	S	41.67	7,500	312,525	69,270	76.8 K to 69.3 K (-9.77 %)
Jun 16 2015	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Buy	M	2.03	7,500	15,225	76,770	69.3 K to 76.8 K (+10.83 %)
Jun 16 2015	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Sell	S	41.29	10,000	412,900	69,270	79.3 K to 69.3 K (-12.62 %)
May 18 2015	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Option Exercise	M	2.03	7,316	14,851	27,043
May 18 2015	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Option Exercise	M	2.03	7,684	15,599	0
May 18 2015	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Sell	S	39.28	7,316	287,372	79,270	86.6 K to 79.3 K (-8.45 %)
May 18 2015	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Buy	M	2.03	7,316	14,851	86,586	79.3 K to 86.6 K (+9.23 %)
May 18 2015	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Sell	S	39.28	7,684	301,828	79,270	87 K to 79.3 K (-8.84 %)
May 18 2015	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Buy	M	2.03	7,684	15,599	86,954	79.3 K to 87 K (+9.69 %)
Jan 09 2015	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Option Exercise	A	39.94	100,000	3,994,000	100,000
Jun 18 2014	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Sell	S	12.51	13,530	169,260	78,463	92 K to 78.5 K (-14.71 %)
Mar 10 2014	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Sell	S	13.65	4,510	61,562	91,993	96.5 K to 92 K (-4.67 %)
Feb 13 2014	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Sell	S	13.92	4,506	62,724	96,503	101 K to 96.5 K (-4.46 %)
Feb 11 2014	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Option Exercise	M	2.03	20,614	41,846	34,359
Feb 11 2014	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Option Exercise	M	2.03	33,295	67,589	7,684
Feb 11 2014	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Option Exercise	M	0.87	34,482	29,999	0
Feb 11 2014	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Sell	S	14.22	9,928	141,176	101,009	110.9 K to 101 K (-8.95 %)
Feb 11 2014	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Buy	M	2.03	20,614	41,846	110,937	90.3 K to 110.9 K (+22.82 %)
Feb 11 2014	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Buy	M	2.03	33,295	67,589	90,323	57 K to 90.3 K (+58.38 %)
Feb 11 2014	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Buy	M	0.87	34,482	29,999	57,028	22.5 K to 57 K (+152.94 %)
Jan 10 2014	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Option Exercise	A	14.99	100,000	1,499,000	100,000
May 17 2013	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Option Exercise	A	7.94	135,000	1,071,900	135,000
Mar 27 2013	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Option Exercise	C	0.00	116,686	0	0
Mar 27 2013	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Option Exercise	C	0.00	115,000	0	0
Mar 27 2013	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Option Exercise	C	0.00	52,173	0	0
Mar 27 2013	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Option Exercise	C	0.00	40,000	0	0
Mar 27 2013	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Buy	C	0.00	4,023	0	22,546	18.5 K to 22.5 K (+21.72 %)
Mar 27 2013	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Buy	C	0.00	3,096	0	18,523	15.4 K to 18.5 K (+20.07 %)
Mar 27 2013	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Buy	C	0.00	1,799	0	14,557	12.8 K to 14.6 K (+14.10 %)
Mar 27 2013	TTPH	TETRAPHASE PHARMAC ...	Lubner David Charles	SVP and CFO	Buy	C	0.00	1,379	0	12,758	11.4 K to 12.8 K (+12.12 %)

Page: 1